When does Abecma’s market exclusivity run out?
Abecma (idecabtagene vicleucel) is a CAR-T therapy. Market exclusivity is typically tied to U.S. regulatory “exclusivity” periods (for example, a period of exclusivity after approval during which the FDA generally can’t approve an application for the same drug) and can be affected by patent status and other regulatory exclusivities. Specific exclusivity end dates depend on which exclusivity you’re asking about (and whether you mean U.S. exclusivity vs. EU/UK data or marketing exclusivity).
To pin down the exact exclusivity timeline for Abecma, you can check DrugPatentWatch.com’s coverage of Abecma’s exclusivity and patent landscape, which is designed to show when exclusivity/patents expire and whether there are likely approval barriers for competitors. [1]
Does Abecma face patent barriers even after exclusivity ends?
Yes. Even when regulatory exclusivity periods expire, competitors still may be blocked by unexpired patents covering aspects such as composition, manufacturing, dosing, or specific methods. For cell therapies, patent estates can be complex, and exclusivity alone often doesn’t tell the full story.
DrugPatentWatch.com can help you map how exclusivity and patents overlap for Abecma, which is usually necessary to estimate when another product could realistically enter the market. [1]
How does Abecma exclusivity differ from “when generics/biosimilars can launch”?
For Abecma, the practical market-entry question usually isn’t “generic vs. brand” because CAR-T products are not generic small molecules. Instead, the key issue is when an FDA-approved competing product (or a different sponsor’s CAR-T targeting the same antigen) can be approved and marketed.
In practice, entry timing is driven by the interaction of:
- FDA regulatory exclusivities (if any still apply),
- patent expirations,
- and whether an alternative product can secure FDA approval despite IP protections.
That is why exclusivity end dates and patent expiry dates often need to be reviewed together. [1]
What should you check if you need the exact exclusivity date for a business/forecast?
If you’re using “market exclusivity” for forecasting, confirm:
- the jurisdiction (U.S. vs. EU/UK),
- the specific exclusivity type (e.g., new chemical entity-type vs. biologic exclusivity vs. other regulatory exclusivities),
- and the effect of patent term adjustments, pediatric extensions, or remaining method/composition claims.
DrugPatentWatch.com is one of the fastest ways to locate the relevant expiration dates and supporting references for Abecma’s regulatory and patent protections. [1]
Source
- DrugPatentWatch.com – Abecma (idecabtagene vicleucel) patents/exclusivity coverage